Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity
- PMID: 36231064
- PMCID: PMC9562038
- DOI: 10.3390/cells11193103
Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity
Abstract
T cells play central roles in the anti-tumor immunity, whose activation and differentiation are profoundly regulated by intrinsic metabolic reprogramming. Emerging evidence has revealed that metabolic processes of T cells are generally altered by tumor cells or tumor released factors, leading to crippled anti-tumor immunity. Therefore, better understanding of T cell metabolic mechanism is crucial in developing the next generation of T cell-based anti-tumor immunotherapeutics. In this review, we discuss how metabolic pathways affect T cells to exert their anti-tumor effects and how to remodel the metabolic programs to improve T cell-mediated anti-tumor immune responses. We emphasize that glycolysis, carboxylic acid cycle, fatty acid oxidation, cholesterol metabolism, amino acid metabolism, and nucleotide metabolism work together to tune tumor-reactive T-cell activation and proliferation.
Keywords: T cell; T cell metabolism; anti-tumor function; tumor microenvironment.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


References
-
- Dammeijer F., van Gulijk M., Mulder E.E., Lukkes M., Klaase L., van den Bosch T., van Nimwegen M., Lau S.P., Latupeirissa K., Schetters S., et al. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell. 2020;38:685–700.e8. doi: 10.1016/j.ccell.2020.09.001. - DOI - PubMed
-
- Lozano A.X., Chaudhuri A.A., Nene A., Bacchiocchi A., Earland N., Vesely M.D., Usmani A., Turner B.E., Steen C.B., Luca B.A., et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 2022;28:353–362. doi: 10.1038/s41591-021-01623-z. - DOI - PMC - PubMed
-
- Watson R.A., Tong O., Cooper R., Taylor C.A., Sharma P.K., de Los Aires A.V., Mahé E.A., Ruffieux H., Nassiri I., Middleton M.R., et al. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8 T cell clone size and cytotoxicity. Sci. Immunol. 2021;6:eabj8825. doi: 10.1126/sciimmunol.abj8825. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical